New gel shows promise for rosacea redness in small study

NCT ID NCT07431476

Completed Symptom relief Sponsor: Istanbul Training and Research Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a gel containing brimonidine to see if it can reduce persistent facial redness in people with rosacea. In the first part, 45 adults applied the gel to one side of their face and a placebo to the other, measuring redness after a few hours. In the second part, they used the gel on both sides daily for one month. Redness was measured with a skin color device, magnified images, and patient reports.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brimonidine gel
What this could lead to: If it works, this could offer a reliable topical option to reduce persistent facial redness in people with rosacea.
What could go wrong: This is a small, completed Phase 4 study with only 45 participants. Results may not apply to all rosacea types, and long-term safety beyond one month is not assessed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ROSACEA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression rosacea telangiectasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ROSACEA ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC)

Contacts and locations

Locations

Istanbul Training and Research Hospital, Department of Dermatology

Istanbul, 34098, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.